Literature DB >> 20689560

Parkinson disease: treatment of the nonmotor symptoms of Parkinson disease.

Werner Poewe.   

Abstract

Dramatic advances have been made in the treatment of motor dysfunction in both the early and late phases of Parkinson disease. Effective therapies for the nonmotor symptoms of this disease, however, remain a major unmet clinical need. A recent study has highlighted the dearth of clinical trials for some of these symptoms.

Entities:  

Mesh:

Year:  2010        PMID: 20689560     DOI: 10.1038/nrneurol.2010.87

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  9 in total

1.  Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Authors:  Paolo Barone; Werner Poewe; Stefan Albrecht; Catherine Debieuvre; Dan Massey; Olivier Rascol; Eduardo Tolosa; Daniel Weintraub
Journal:  Lancet Neurol       Date:  2010-05-07       Impact factor: 44.182

Review 2.  Invited Article: Nervous system pathology in sporadic Parkinson disease.

Authors:  Heiko Braak; Kelly Del Tredici
Journal:  Neurology       Date:  2008-05-13       Impact factor: 9.910

3.  Rivastigmine for dementia associated with Parkinson's disease.

Authors:  Murat Emre; Dag Aarsland; Alberto Albanese; E Jane Byrne; Günther Deuschl; Peter P De Deyn; Franck Durif; Jaime Kulisevsky; Teus van Laar; Andrew Lees; Werner Poewe; Alain Robillard; Mario M Rosa; Erik Wolters; Peter Quarg; Sibel Tekin; Roger Lane
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

4.  Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  T A Zesiewicz; K L Sullivan; I Arnulf; K R Chaudhuri; J C Morgan; G S Gronseth; J Miyasaki; D J Iverson; W J Weiner
Journal:  Neurology       Date:  2010-03-16       Impact factor: 9.910

5.  Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  J M Miyasaki; K Shannon; V Voon; B Ravina; G Kleiner-Fisman; K Anderson; L M Shulman; G Gronseth; W J Weiner
Journal:  Neurology       Date:  2006-04-11       Impact factor: 9.910

Review 6.  Treatments for Parkinson disease--past achievements and current clinical needs.

Authors:  Werner Poewe
Journal:  Neurology       Date:  2009-02-17       Impact factor: 9.910

7.  Dopamine miracle: from brain homogenate to dopamine replacement.

Authors:  Oleh Hornykiewicz
Journal:  Mov Disord       Date:  2002-05       Impact factor: 10.338

8.  The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.

Authors:  Mariese A Hely; Wayne G J Reid; Michael A Adena; Glenda M Halliday; John G L Morris
Journal:  Mov Disord       Date:  2008-04-30       Impact factor: 10.338

9.  Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease--a retrospective comparison.

Authors:  M Magalhães; G K Wenning; S E Daniel; N P Quinn
Journal:  Acta Neurol Scand       Date:  1995-02       Impact factor: 3.209

  9 in total
  6 in total

Review 1.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 2.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

Review 3.  Therapeutic approaches in Parkinson's disease and related disorders.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

Review 4.  Nrf2: a modulator of Parkinson's disease?

Authors:  Michael Todorovic; Stephen A Wood; George D Mellick
Journal:  J Neural Transm (Vienna)       Date:  2016-05-04       Impact factor: 3.575

Review 5.  Targeting the Dopaminergic System in Autoimmunity.

Authors:  Pia M Vidal; Rodrigo Pacheco
Journal:  J Neuroimmune Pharmacol       Date:  2019-01-19       Impact factor: 4.147

Review 6.  Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.

Authors:  Sumit Sarkar; James Raymick; Syed Imam
Journal:  Int J Mol Sci       Date:  2016-06-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.